Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Multiple Myeloma × Immunotherapy × Clear all

Phase

Status

Withdrawn 1 Unknown 1 Terminated 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Melanoma 2 Skin Neoplasms 1 Prostatic Neoplasms 1 Neoplasms 1 Neoplasm Metastasis 1 Multiple Myeloma 1 Cholangiocarcinoma 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma, Merkel Cell 1 Carcinoma, Hepatocellular 1 Carcinoma, Basal Cell 1 Breast Neoplasms 1 Autoimmune Diseases 1

Interventions

Dexamethasone 88 Bortezomib 52 Cyclophosphamide 44 Lenalidomide 40 Calcium Dobesilate 36 pomalidomide 26 Melphalan 26 fludarabine 22 Filgrastim 20 carfilzomib 19 fludarabine phosphate 15 daratumumab 14 Whole-Body Irradiation 13 Mycophenolic Acid 13 Granulocyte Colony-Stimulating Factor 13 Antilymphocyte Serum 13 dexamethasone acetate 12 Thalidomide 12 Cyclosporine 12 Tacrolimus 10 Peripheral Blood Stem Cell Transplantation 10 dexamethasone 21-phosphate 9 auricularum 9 Radiotherapy 9 Busulfan 9 belantamab mafodotin 8 Etoposide 8 pembrolizumab 7 ixazomib 7 Stem Cell Transplantation 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03634800 2021-08-05

RISE-M

Weill Medical College of Cornell University

Phase 2 Terminated

6 enrolled 11 charts

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡